SCHEMBL29859616

SCHEMBL29859616

Cc1cc(Nc2ncc3c(n2)N2CCN=C2N(c2c(Cl)cccc2Cl)C3=O)cc(Br)c1N1C[C@@H](C)N(C)[C@@H](C)C1

nearest known ligand 0.65

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ WEE1 P30291 19/20 0.65
▸ SIK2 Q9H0K1 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23263117 1.00 WEE1 (0.65) WEE1SIK2CYP3A4
SCHEMBL29859410 0.95 WEE1 (0.69) WEE1SIK2CYP3A4
SCHEMBL23263115 0.95 WEE1 (0.69) WEE1SIK2CYP3A4
SCHEMBL21373451 0.94 WEE1 (0.68) WEE1SIK2CYP3A4
SCHEMBL29506539 0.94 WEE1 (0.68) WEE1SIK2CYP3A4
SCHEMBL29859347 0.92 WEE1 (0.78) WEE1CYP3A4
SCHEMBL23246115 0.92 WEE1 (0.78) WEE1CYP3A4
SCHEMBL21373325 0.91 WEE1 (0.69) WEE1SIK2CYP3A4
SCHEMBL29506460 0.91 WEE1 (0.69) WEE1SIK2CYP3A4
SCHEMBL21373392 0.91 WEE1 (0.63) WEE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN claimed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO claimed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO claimed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN disclosed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO disclosed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO disclosed
Send feedback